Market Overview

Gilead Volatile After Kite Pharma's Yescarta Gets FDA Approval

Related GILD
IMX Dips In October, But Investors Remain Bullish
Investor Movement Index October Summary
Tesaro Is Now An Attractive Acquisition Target (Seeking Alpha)

Gilead Sciences, Inc. (NASDAQ: GILD) shares are trading higher by 80 cents (1 percent) at $80.81 in Thursday's session.

After Wednesday's close, subsidiary Kite Pharma announced FDA approval for Yescarta, a gene-altering treatment for cancer.

After a higher open, Gilead continued in that direction before finally peaking at $82.47 and reversed course. That high comes just under its Oct. 12 high ($82.82).

The stock has come hard off that level and so far found intraday support just under the upper-range of Wednesday's ($80.84) as $80.52 stands as the low for the session as of 10:30 a.m. EST.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (GILD)

View Comments and Join the Discussion!

Verizon Higher After Q2 Report

Baker Hughes, A Compelling Stock For The Conservative Investor